{
    "clinical_study": {
        "@rank": "68823", 
        "arm_group": [
            {
                "arm_group_label": "VISION5 Product", 
                "arm_group_type": "Experimental", 
                "description": "VISION5 Product in both eyes and placebo drops twice a day in each eye."
            }, 
            {
                "arm_group_label": "Timolol 0.5% + Placebo VISION5 Product", 
                "arm_group_type": "Active Comparator", 
                "description": "Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus VISION5 Placebo Product"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this Phase 2 study is to evaluate whether the VISION5 Product is\n      non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks."
        }, 
        "brief_title": "VISION5 Product Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Open-Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Primary open-angle glaucoma or ocular hypertension in both eyes\n\n          -  Best-corrected distance vision of 20/80 or better\n\n          -  Stable visual field\n\n          -  corneal thickness between 490-620 micrometers\n\n        Key Exclusion Criteria:\n\n          -  Cup-to-disc ratio greater than 0.8\n\n          -  significant risk of angle closure due to pupil dilation, defined as a Shaffer\n             classification of less than grade 2 based on gonioscopy\n\n          -  laser surgery for glaucoma/ocular hypertension on one or both eyes within the last 12\n             months\n\n          -  past history of corneal refractive surgery\n\n          -  past history of any incisional surgery for glaucoma at any time\n\n          -  corneal abnormalities that would interfere with tonometry readings\n\n          -  current participation in an investigational drug or device study or participation in\n             such a study within 30 days of screening\n\n          -  Inability to accurately evaluate the retina"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "126", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01915940", 
            "org_study_id": "FSV5-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "VISION5 Product", 
                "intervention_name": "VISION5 Product", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Timolol 0.5% + Placebo VISION5 Product", 
                "description": "0.5% solution", 
                "intervention_name": "Timolol", 
                "intervention_type": "Drug", 
                "other_name": "timoptic"
            }, 
            {
                "arm_group_label": "VISION5 Product", 
                "description": "placebo topical eye drops", 
                "intervention_name": "Placebo drops", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Timolol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Glaucoma", 
            "Primary Open-Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": {
            "contact": {
                "email": "jdbrandt@ucdavis.com", 
                "last_name": "James Brandt, MD", 
                "phone": "916-734-6969"
            }, 
            "facility": {
                "address": {
                    "city": "Sacramento", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "95817"
                }, 
                "name": "UC Davis Dept of Ophthalmology & Vision Science"
            }, 
            "investigator": {
                "last_name": "James Brandt, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the ForSight VISION5 Product as Compared to the Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension", 
        "overall_contact": {
            "email": "gwalker@forsightv5.com", 
            "last_name": "Gary A Walker, PhD", 
            "phone": "650-325-2050"
        }, 
        "overall_contact_backup": {
            "email": "arubin@forsightv5.com", 
            "last_name": "Anne Rubin", 
            "phone": "650-325-2050"
        }, 
        "overall_official": {
            "affiliation": "University of California, Davis", 
            "last_name": "James D Brandt, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ocular Tonometry", 
            "safety_issue": "No", 
            "time_frame": "12 weeks post randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01915940"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Ocular Tonometry", 
            "safety_issue": "No", 
            "time_frame": "6-months"
        }, 
        "source": "ForSight Vision5, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ForSight Vision5, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}